Leflunomide is a DMARD medication

Lefluno­mide is a DMARD medication

Lefluno­mide is a DMARD med­ica­tion of the type used in activ­i­ties of mod­er­ate to severe rheuma­toid arthri­tis and pso­ri­atic arthri­tis. It is a pyrim­i­dine syn­the­sis inhibitor. Mechanism

Lefluno­mide is an immunomod­u­la­tory agent inhibits dihy­drooro­tate (an enzyme involved in de novo pyrim­i­dine biosyn­the­sis) (DHODH short­en­ing). Real antipro­lif­er­a­tive activ­ity was detected. In addi­tion, sev­eral exper­i­men­tal mod­els (both in vivo and in vitro) revealed an anti-inflammatory. This dou­ble action is intended to slow the pro­gres­sion of the dis­ease and induce remis­sion / relief of symp­toms of rheuma­toid arthri­tis and pso­ri­atic arthri­tis as pain and decreased joint mobil­ity and gen­eral in humans.

lefluno­mide is dmard

Reg­u­lar information

In U. S. Arava is indi­cated in adults for the treat­ment of mod­er­ate to severe rheuma­toid arthri­tis and psoriatic

* To reduce the signs and symptoms

* In order to inhibit struc­tural dam­age as evi­denced by X-ray ero­sions and joint space nar­row­ing fun

* In order to improve phys­i­cal function.

The onset of clin­i­cal improve­ment can be expected after 4 to 6 weeks of con­tin­u­ous treatment.

Aspirin or other non­s­teroidal anti-inflammatory (will be), and / or low dose cor­ti­cos­teroids may be con­tin­ued dur­ing treat­ment with lefluno­mide. The com­bined use of lefluno­mide with anti­malar­i­als, intra­mus­cu­lar or oral gold, D peni­cil­lamine, aza­thio­prine or methotrex­ate is not ade­quately stud­ied and is there­fore contraindicated.

Par­tic­u­larly with con­comi­tant use of methotrex­ate may cause seri­ous or fatal liver or liver tox­i­c­ity. Sev­enty per­cent of all cases of severe liver injury reported in early 2001 was seen by a com­bined treat­ment with med­i­cines, Arava plus methotrexate.

Note that Dr. Arava should be pre­scribed only by spe­cial­ists expe­ri­enced in the treat­ment of rheumatic diseases.

Unwanted

The side effects of Arava affect sys­tems of many organs, are fre­quent and some­times severe or lethal.

* The most seri­ous dam­age to the liver symp­to­matic jaun­dice of hepati­tis, which can be ful­mi­nant, severe hepatic necro­sis and cir­rho­sis. Fatal­i­ties are known. Liver func­tion tests may or may not pre­cede the out­breaks of clin­i­cal dis­ease. The over­all inci­dence of seri­ous liver dam­age is esti­mated to be 0.5%, accord­ing to an inter­nal report by the FDA. EMEA, the Euro­pean coun­ter­part to the FDA in 2001 reported 296 cases of hepa­to­tox­i­c­ity in 104,000 patient-years, with 129 clas­si­fied as seri­ous, 2 cases of cir­rho­sis and 15 cases of liver fail­ure. Nine of the patients died. EMEA results is that the liver dam­age is usu­ally seen within the first 6 months of treat­ment and is par­tially depen­dent on cofac­tors, because of the seri­ous cases, 101 (78%) received con­comi­tant ther­apy with other hepa­to­toxic med­ica­tions, 58% of asymp­to­matic liver func­tion tests were cotreated with some nIt will be and / or methotrex­ate (see con­traindi­ca­tions). More­over, (33% = 27 patients) of patients with seri­ous injuries were other risk fac­tors (his­tory of alco­hol abuse, liver dys­func­tion, heart fail­ure, acute, seri­ous ill­ness or can­cer of the pan­creas). Analy­sis of the data sug­gests that mon­i­tor­ing of liver func­tion tests and wash-out peri­ods may not have been fully met. For ques­tions, please refer to the pro­ce­dures pro­posed in the dec­la­ra­tion EMEA, as for the exter­nal links sec­tion and references.

* Also very impor­tant is the rel­a­tively high inci­dence of myelo­sup­pres­sion with leukope­nia and / or hypoplas­tic ane­mia, and / or throm­bo­cy­tope­nia. Infec­tions, some­times so severe that the devel­op­ment of active tuber­cu­lo­sis, pneu­mo­nia, PCP, and seri­ous viral infec­tions or mycot­i­cal, can lead to sep­sis, death or per­ma­nent dam­age was seen. Episodes of ane­mia or bleed­ing can also lead to seri­ous complications.

* Inter­sti­tial lung dis­ease can be iden­ti­fied and rec­og­nized by a pro­gres­sive dys­p­nea and typ­i­cal radi­ographic find­ings. This dis­ease may or may not be annulled by the treat­ment and can lead to per­ma­nent dis­abil­ity or death.

* Other loca­tions: GIT, skin reac­tions to life-threatening forms (Stevens-Johnson syn­drome and toxic epi­der­mal necrol­y­sis, heart prob­lems, alope­cia (17.1%), CNS prob­lems, etc.

If seri­ous side effects occurred, ter­i­fluno­mide can be eas­ily removed from the body with cholestyra­mine or acti­vated char­coal orally (see above) to reduce or nul­lify the observed effect.